[EQ] Economic Impact of Dengue Illness in the Americas

Economic Impact of Dengue Illness in the Americas

Donald S. Shepard*, Laurent Coudeville, Yara A. Halasa, Betzana Zambrano, AND Gustavo H. Dayan

Brandeis University, Waltham, Massachusetts; Sanofi Pasteur, Lyon, France; Sanofi Pasteur, Swiftwater, Pennsylvania

Am. J. Trop. Med. Hyg., 84(2), 2011, pp. 200-207 doi:10.4269/ajtmh.2011.10-0503; The American Society of Tropical Medicine and Hygiene

Abstract.: http://bit.ly/gYVJE6

“……The growing burden of dengue in endemic countries and outbreaks in previously unaffected countries stress the need to assess the economic impact of this disease. This paper synthesizes existing studies to calculate the economic burden of dengue illness in the Americas from a societal perspective. Major data sources include national case reporting data from 2000 to 2007, prospective cost of illness studies, and analyses quantifying underreporting in national routine surveillance systems.

Dengue illness in the Americas was estimated to cost $2.1 billion per year on average (in 2010 US dollars), with a range of $1–4 billion in sensitivity analyses and substantial year to year variation. The results highlight the substantial economic burden from dengue in the Americas. The burden for dengue exceeds that from other viral illnesses, such as human papillomavirus (HPV) or rotavirus. Because this study does not include some components (e.g., vector control), it may still underestimate total economic consequences of dengue.

Health Economics of Dengue:
A Systematic Literature Review and Expert Panel's Assessment

Mark E. Beatty, Philippe Beutels, Martin I. Meltzer, Donald S. Shepard, Joachim Hombach, Raymond Hutubessy, Damien Dessis, Laurent Coudeville, Benoit Dervaux, Ole Wichmann, Harold S. Margolis, AND Joel N. Kuritsky

Pediatric Dengue Vaccine Initiative, International Vaccine Institute, Seoul, Republic of Korea; Centre for Health Economics Research and Modeling Infectious Diseases, Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, Antwerp, Belgium; Centers for Disease Control and Prevention, Atlanta, Georgia; Heller School, Brandeis University, Waltham, Massachusetts; Initiative for Vaccine Research, World Health Organization, Geneva, Switzerland; GlaxoSmithKline Biologicals, Wavre, Belgium; Sanofi Pasteur, Lyon, France; Université Catholique de Lille, Lille, France

Am. J. Trop. Med. Hyg., 84(3), 2011, pp. 473-488 doi:10.4269/ajtmh.2011.10-0521;The American Society of Tropical Medicine and Hygiene

Abstract.: http://bit.ly/h5BZZ8

“……Dengue vaccines are currently in development and policymakers need appropriate economic studies to determine their potential financial and public health impact. We searched five databases (PubMed, EMBASE, LILAC, EconLit, and WHOLIS) to identify health economics studies of dengue. Forty-three manuscripts were identified that provided primary data: 32 report economic burden of dengue and nine are comparative economic analyses assessing various interventions. The remaining two were a willingness-to-pay study and a policymaker survey.

An expert panel reviewed the existing dengue economic literature and recommended future research to fill information gaps.
Although dengue is an important vector-borne disease, the economic literature is relatively sparse and results have often been conflicting because of use of inconsistent assumptions. Health economic research specific to dengue is urgently needed to ensure informed decision making on the various options for controlling and preventing this disease. …”

 *      *      *     *
This message from the Pan American Health Organization, PAHO/WHO, is part of an effort to disseminate
information Related to: Equity; Health inequality; Socioeconomic inequality in health; Socioeconomic
health differentials; Gender; Violence; Poverty; Health Economics; Health Legislation; Ethnicity; Ethics;
Information Technology - Virtual libraries; Research & Science issues.  [DD/ KMC Area]

“Materials provided in this electronic list are provided "as is". Unless expressly stated otherwise, the findings
and interpretations included in the Materials are those of the authors and not necessarily of The Pan American
Health Organization PAHO/WHO or its country members”.
------------------------------------------------------------------------------------

PAHO/WHO Website: http://new.paho.org/equity/

EQUITY List - Archives - Join/remove: http://listserv.paho.org/Archives/equidad.html

Twitter http://twitter.com/eqpaho

IMPORTANT: This transmission is for use by the intended
recipient and it may contain privileged, proprietary or
confidential information. If you are not the intended
recipient or a person responsible for delivering this
transmission to the intended recipient, you may not
disclose, copy or distribute this transmission or take
any action in reliance on it. If you received this transmission
in error, please dispose of and delete this transmission.

Thank you.